AKYNZEO® inhibits the receptors that drive acute and delayed CINV1

5-HT3 + NK-1 RA combination inhibits 2 nausea and vomiting pathways

MOA Diagram 1

Durable half-life demonstrated across formulations

MOA Diagram 2

*Observed in clinical studies of cancer patients.

Based on netupitant concentration after IV injection.

Fosnetupitant half-life was 144 hours in cancer patients

Fosnetupitant, a prodrug of netupitant, is converted in vivo to netupitant.

Lasting receptor occupancy and strong binding affinity1

  • Netupitant demonstrated NK-1 receptor occupancy of ≥76% through 96 hours
  • Palonosetron has a strong binding affinity for 5-HT3 receptors

AKYNZEO combines 2 agents for inhibitor activities across the continuum of acute and delayed CINV1

  • 5-HT3=5-hydroxytryptamine; CINV=chemotherapy-induced nausea and vomiting; IV=intravenous; NK-1=neurokinin-1; RA=receptor antagonist.